Bluebird Bio Is Liked by Analysts, Cognizant Isn't

RATINGS CHANGES

Bluebird Bio (BLUE) was upgraded to outperform and assigned a $108 price target at BMO.

Cognizant (CTSH) was downgraded to hold and assigned a $74 price target at Societe Generale.

Gardner Denver (GDI) was initiated with a buy rating and $27 price target at Stifel.

Gardner Denver was also initiated with an overweight rating and $27 price target at Piper Jaffray.

Hormel (HRL) was initiated with an overweight rating and $38 price target at Barclays.

Novartis (NVS) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: NVS.

Sanderson Farms (SAFM) was initiated with an equal-weight rating and $125 price target at Barclays.

Tenet Healthcare (THC) was upgraded to outperform and assigned a $21.50 price target at Wells Fargo.

Tyson Foods (TSN) was initiated with an overweight rating and $70 price target at Barclays.

This article was written by a staff member of TheStreet.

More from Stocks

Amazon's Cloud-Market Lead Is Being Threatened by Microsoft

Amazon's Cloud-Market Lead Is Being Threatened by Microsoft

Stocks Push to Session Highs During Fed Chair's Congressional Testimony

Stocks Push to Session Highs During Fed Chair's Congressional Testimony

Goldman Sachs: Cash and Commodities Are King

Goldman Sachs: Cash and Commodities Are King

Could Tesla's Model 3 Be the Best-Selling Sedan in the Second Half of 2018?

Could Tesla's Model 3 Be the Best-Selling Sedan in the Second Half of 2018?

Wall Street Ignores $5 Billion EU Fine Against Alphabet

Wall Street Ignores $5 Billion EU Fine Against Alphabet